Specialized Clozapine Clinic for Bipolar and Schizoaffective Disorder

NCT ID: NCT00683709

Last Updated: 2011-08-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

48 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-01-31

Study Completion Date

2011-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Bipolar Disorder (BD) and Schizoaffective Disorder (SA) clients.

* determine if after 12 months of treatment with clozapine, the BMI changes with clients who are councelled as usual regarding weight gain while on Clozapine.
* determine if after 12 months of treatment with clozapine, the BMI changes with intense, structured councelling about diet and exercise.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To determine whether the changes in BMI produced in subjects with Bipolar Disorder (BD) and Schizoaffective Disorder (SA) by 12 months of treatment with clozapine, can be diminished after an intense and highly structured intervention focused on diet and exercise, compared with the usual brief counseling regarding weight gain on this drug.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bipolar Affective Disorder Schizoaffective Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Counselling as Usual

Discussing Clozapine medication, diet and exercise as per clinical protocol potential weight changes

Counselling as Usual

Intervention Type BEHAVIORAL

5 - 20 minutes, about the effects of clozapine on body weight, appetite, blood sugar and fats such as cholesterol and triglycerides in the blood, and how these might affect your health in the future.

Cognitive Behavoural Therapy

Counselling about Clozapine medication, diet and exercise in a structured fashion using Cognitive Behavioural Therapy about potential weight changes

CBT

Intervention Type BEHAVIORAL

45 - 60 minutes individual treatment sessions focused on nutrition, exercise and weight control and will occur weekly for 4 weeks. After this, 10 group sessions focused on weight reduction will be held every 2 weeks. This will be followed by 6 group sessions focused on weight maintenance held every 2 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Counselling as Usual

5 - 20 minutes, about the effects of clozapine on body weight, appetite, blood sugar and fats such as cholesterol and triglycerides in the blood, and how these might affect your health in the future.

Intervention Type BEHAVIORAL

CBT

45 - 60 minutes individual treatment sessions focused on nutrition, exercise and weight control and will occur weekly for 4 weeks. After this, 10 group sessions focused on weight reduction will be held every 2 weeks. This will be followed by 6 group sessions focused on weight maintenance held every 2 weeks.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clients diagnosed with bipolar disorder or schizoaffective disorder
* Clients who respond poorly to treatment
* Males and females ages 18 years or older
* Clients who have had a trial of antipsychotics, incl. at least one atypical antipsychotic plus at least 2 mood stabilizers
* Clients who are capable of providing informed consent

Exclusion Criteria

* Clients who take carbamazepine
* Clients with a history of extremely low white blood counts
* Clients with severe kidney, liver or heart disease, or heart operation
* Clients are hypersensitive to clozapine
* Clients who have a history of serious side effects after previous treatment with clozapine
* Clients with alcohol or drugs abuse within the last 3 months
* Clients who have a seizure disorder
* Clients who have metal in the head, neck or eyes, shrapnel, bullets, or body piercing, a pacemaker, brain aneurism clips, cochlear implant, hearing aid, tens unit, spinal implant, or pregnancy. These safety measures are necessary because of the magnetic fields of the MRI scan.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

St. Joseph's Healthcare Hamilton

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

McMaster University

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gary Hasey, MD

Role: PRINCIPAL_INVESTIGATOR

St. Joseph's Healthcare and McMaster University, Hamilton

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

St. Joseph's Healthcare, Centre for Mountain Health Services

Hamilton, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

06-2726

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Clozapine for Treatment-Resistant Mania
NCT00029458 COMPLETED PHASE2
Exercise and Olanzapine-samidorphan
NCT06740890 RECRUITING PHASE4
Short Term Rescue Study of Olanzapine
NCT00186017 COMPLETED PHASE4